Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]GEH121224 PET Imaging in HER2+ Breast Cancer
NCT05634954Phase 1Withdrawn
- Sponsor
- GE HealthCare
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluorine F 18 + GEH121224 in breast cancer, sponsored by GE HealthCare. Primary endpoints: Specific absorbed dose to target lesions and organs at 6 months, Change in injection site status and 6 more. Planned start Feb 2026; status: withdrawn.
02
Drugs
fluorine F 18 + GEH121224
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05634954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634954.